STA
ESPR

Summit Trail Advisors’s Esperion Therapeutics ESPR Stock Holding History

Summit Trail Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-520
Closed -$20K – 338
2018
Q2 		$20K Buy
+520
New +$26.3K 0.01% 380
2018
Q1 		– Sell
-1,450
Closed -$101K – 813
2017
Q4 		$101K Buy
+1,450
New +$78.1K 0.01% 622

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Summit Trail Advisors's ESPR Position: Q3 2018 in Review

Summit Trail Advisors sold out of Esperion Therapeutics (ESPR) in Q3 2018, closing a stake of 520 shares — an estimated $20K sold.

Summit Trail Advisors first reported a position in ESPR in Q4 2017 and held it in 2 quarters. The position peaked at $101K in Q4 2017. 155 funds tracked by Wall St. Rank hold ESPR as of Q3 2018.

  • Summit Trail Advisors reported no remaining Esperion Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 520 Esperion Therapeutics shares in Q3 2018, an estimated $20K.
  • Summit Trail Advisors first reported a position in Esperion Therapeutics in Q4 2017 and held it in 2 quarters.
  • Summit Trail Advisors's Esperion Therapeutics position peaked at $101K in Q4 2017.
  • 155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2018.

Based on Summit Trail Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.